Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
747 A phase 1 trial of IO-202, an antagonist antibody targeting myeloid checkpoint LILRB4 (ILT3), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.